Path To a Cure – Collaborative Research Grant 2024
19 July 2024Macular Degeneration Research Grants 2024
19 July 2024Through this call, reuse clinical trials will be financed to treat unsolved blood cancers, with preference for trials that affect multiple myeloma and/or myelodysplastic syndromes. Priority will be given to approved generic or patented therapies that can be repurposed to create new treatments that:
- Restore the lost function.
- Reduce symptoms, progression or incidence.
- Reduce or eliminate serious side effects of currently used therapies for any blood cancer, thereby improving patient outcomes and quality of life.
Accredited academics, government and non-profit research institutions, and health systems involved in medical research from anywhere in the world can participate. However, startups, pharmaceutical companies and biotechnology or health device companies will be rejected, although their collaborators in eligible institutions will be able to participate.
The submitted proposal must contain a therapy approved and/or generally recognized as safe for human use by a regulatory agency, such as the European Medicines Agency. It must also be led by both a researcher who has previously received funding, and one who has received little or no external funding to date.
Deadline: 29 of Julio of 2024.